On April 10, 2024, the Court rendered a judgment authorizing the class action.
The judgment modifies the definition of the Class as follows :
All persons in Quebec who have been prescribed and consumed any one or more of the opioids medications identified in Schedule I attached hereto, manufactured, marketed, distributed and/or sold by the Defendants between 1996 and the present day (“Class Period”) and who have been diagnosed by a physician as suffering or having suffered from Opioid Use Disorder.
The Class excludes any person whose claim, or any portion thereof, is in relation to the drugs OxyContin and OxyNEO, as well as in relation to opioid drugs that were solely and exclusively available for use in a hospital setting and not prescribed for use in the home.
The Class also includes the direct heirs of any deceased person who during his or her lifetime met the above description, subject to the same exclusions.
The defendants have confirmed that they intend to seek permission to appeal this decision. More information will follow.
For more information, you can visit our page dedicated to this class action.
